Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells

Carcinogenesis

Volumn 34, Issue 3, 2013, Pages 703-712

  Dairkee, Shanaz H ^a   Luciani Torres, M Gloria ^a   Moore, Dan H ^a   Goodson, William H ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; CURCUMIN; MAMMALIAN TARGET OF RAPAMYCIN; POLYPHENOL; PROTEIN P53;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE; CELL DEATH; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZHYDRYL COMPOUNDS; BREAST NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; CURCUMIN; DOWN-REGULATION; EPITHELIAL CELLS; ESTROGEN RECEPTOR ALPHA; ESTROGENS, NON-STEROIDAL; FEMALE; HUMANS; HYDROXYTESTOSTERONES; KINETICS; MAMMARY GLANDS, HUMAN; PHENOLS; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874765558     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs379     Document Type: Article

References (42)

1. Statistics Canada. Bisphenol A concentrations in the Canadian population, 2007 to 2009. http://www.statcan.gc.ca/pub/82-003-x/2010003/article/11324/tbl/tbl1-eng.htm (16 August 2010, last date modified).
2. Calafat, A.M. et al. (2008) Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ. Health Perspect., 116, 39-44.
3. Goodson, W.H. 3rd et al. (2011) Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women. Carcinogenesis, 32, 1724-1733.
4. Rossouw, J.E. et al. Writing Group for the Women's Health Initiative Investigators. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288, 321-333.
5. Goss, P.E. et al. (2011) Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med., 364, 2381-2391.
6. Fisher, B. et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst., 90, 1371-1388.
7. Colerangle, J.B. et al. (1997) Profound effects of the weak environmental estrogen-like chemical bisphenol A on the growth of the mammary gland of Noble rats. J. Steroid Biochem. Mol. Biol., 60, 153-160.
8. Vandenberg, L.N. et al. (2007) Exposure to environmentally relevant doses of the xenoestrogen bisphenol-A alters development of the fetal mouse mammary gland. Endocrinology, 148, 116-127.
9. Tharp, A.P. et al. (2012) Bisphenol A alters the development of the rhesus monkey mammary gland. Proc. Natl Acad. Sci. U.S.A., 109, 8190-8195.
10. Dairkee, S.H. et al. (2008) Bisphenol A induces a profile of tumor aggressiveness in high-risk cells from breast cancer patients. Cancer Res., 68, 2076-2080.
11. Sabatini, D.M. (2006) mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer, 6, 729-734.
12. Beevers, C.S. et al. (2009) Curcumin disrupts the mammalian target of rapamycin-raptor complex. Cancer Res., 69, 1000-1008.
13. Han, X. et al. (2012) Curcumin inhibits protein phosphatases 2A and 5, leading to activation of mitogen-activated protein kinases and death in tumor cells. Carcinogenesis, 33, 868-875.
14. Fajardo, A.M. et al. (2012) The curcumin analog ca27 down-regulates androgen receptor through an oxidative stress mediated mechanism in human prostate cancer cells. Prostate, 72, 612-625.
15. Chaudhary, L.R. et al. (2003) Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J. Cell. Biochem., 89, 1-5.
16. Shaaban, A.M. et al. (2003) Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am. J. Surg. Pathol., 27, 1502-1512.
17. Konstantin, C. et al. (1991) Proliferation of normal breast epithelial cells as shown by in vivo labeling with bromodeoxyuridine. Am. J. Pathol., 138, 1371-1377.
18. Krishnan, A.V. et al. (1993) Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. Endocrinology, 132, 2279-2286.
19. Lamartiniere, C.A. et al. (2011) Exposure to the endocrine disruptor bisphenol A alters susceptibility for mammary cancer. Horm. Mol. Biol. Clin. Investig., 5, 45-52.
20. Oltvai, Z.N. et al. (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74, 609-619.
21. Varley, J.M. et al. (1997) Li-Fraumeni syndrome-a molecular and clinical review. Br. J. Cancer, 76, 1-14.
22. Gu, J. et al. (2001) Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain. Cancer Res., 61, 1741-1746.
23. Murray, T.J. et al. (2007) Induction of mammary gland ductal hyperplasias and carcinoma in situ following fetal bisphenol A exposure. Reprod. Toxicol., 23, 383-390.
24. Todorov, I.T. et al. (1991) Nuclear matrix protein mitotin messenger RNA is expressed at constant levels during the cell cycle. Biochem. Biophys. Res. Commun., 177, 395-400.
25. Moldovan, G.L. et al. (2007) PCNA, the maestro of the replication fork. Cell, 129, 665-679.
26. Volarevic, S. et al. (2000) Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. Science, 288, 2045-2047.
27. Armengol, G. et al. (2007) 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res., 67, 7551-7555.
28. Satyanarayana, A. et al. (2009) Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene, 28, 2925-2939.
29. Ramachandran, C. et al. (1999) Differential sensitivity of human mammary epithelial and breast carcinoma cell lines to curcumin. Breast Cancer Res. Treat., 54, 269-278.
30. Verma, S.P. et al. (1998) The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and isoflavonoids. Environ. Health Perspect., 106, 807-812.
31. Yu, J. et al. (2006) Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain. Cancer Res., 66, 9461-9466.
32. Miller, T.W. et al. (2010) Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J. Clin. Invest., 120, 2406-2413.
33. Dookeran, K.A. et al. (2010) p53 as a marker of prognosis in African-American women with breast cancer. Ann. Surg. Oncol., 17, 1398-1405.
34. Lykkesfeldt, A.E. et al. (1986) Cell cycle analysis of estrogen stimulation and antiestrogen inhibition of growth of the human breast cancer cell line MCF-7. Breast Cancer Res. Treat., 7 Suppl, S83-S90.
35. Miecznikowski, J.C. et al. (2010) Comparative survival analysis of breast cancer microarray studies identifies important prognostic genetic pathways. BMC Cancer, 10, 573.
36. Schultz-Norton, J.R. et al. (2007) Interaction of estrogen receptor α with proliferating cell nuclear antigen. Nucleic Acids Res., 35, 5028-5038.
37. Gonzalez, M.A. et al. (2003) Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J. Clin. Oncol., 21, 4306-4313.
38. Dairkee, S.H. et al. (2007) Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome. Oncogene, 26, 6269-6279.
39. Sayeed, A. et al. (2007) Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res., 67, 7746-7755.
40. Hall, J.M. et al. (1999) The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology, 140, 5566-5578.
41. Teeguarden, J.G. et al. (2011) Twenty-four hour human urine and serum profiles of bisphenol a during high-dietary exposure. Toxicol. Sci., 123, 48-57.
42. Baselga, J. et al. (2012) Everolimus in postmenopausal hormone-receptorpositive advanced breast cancer. N. Engl. J. Med., 366, 520-529.